Half-Dose Radiopharmaceutical in Wide Beam Reconstruction (REGA-1102)
Feasibility of Half-Dose Radiopharmaceutical Administration Utilizing Wide-Beam Reconstruction
Sponsor: Astellas Pharma Global Development, Inc.
Terminated
Low enrollment
Other terminated trials from Astellas Pharma Global Development, Inc.
- Carcinoma Transitional Cell · Phase PHASE1 · Sep 2025
- Solid Tumor · Phase PHASE1 · Sep 2025
- Acute Myeloid Leukemia (AML) · Phase PHASE1/PHASE2 · Mar 2025
- B-cell Lymphoma · Phase PHASE1 · Dec 2024
- Advanced Solid Tumors · Phase PHASE1 · Oct 2024
More terminations from Astellas Pharma Global Development, Inc.
Other Ischemic Heart Disease trials with similar outcome
Listed as NCT01499654, this NA trial focuses on Ischemic Heart Disease and Myocardial Infarction and remains terminated or withdrawn. Sponsored by Astellas Pharma Global Development, Inc., it has been updated 9 times since 2011, reflecting limited change activity. This study contributes longitudinal data to the cardiovascular research landscape.
Status Flow
Change History
9 versions recorded-
Sep 2024 — Present [monthly]
Terminated NA
-
Jul 2024 — Sep 2024 [monthly]
Terminated NA
-
Jan 2023 — Jul 2024 [monthly]
Terminated NA
-
Dec 2022 — Jan 2023 [monthly]
Terminated NA
-
Dec 2021 — Dec 2022 [monthly]
Terminated NA
▶ Show 4 earlier versions
-
Jan 2021 — Dec 2021 [monthly]
Terminated NA
-
Jun 2018 — Jan 2021 [monthly]
Terminated NA
-
Feb 2017 — Jun 2018 [monthly]
Terminated NA
-
Jan 2017 — Feb 2017 [monthly]
Terminated NA
First recorded
Oct 2011
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Astellas Pharma Global Development, Inc.
- Edwin Wu
For direct contact, visit the study record on ClinicalTrials.gov .